BNR (brbiotech.com) Company Net Assets

Burning Rock Biotech (BNR) business is subject to Chinese government regulation and price wars, which, coupled with geopolitical tensions, limits profitability. The company relies on the liquid biopsy segment, where a narrow profile is offset by global growth in screening demand. High physician confidence in the accuracy of NGS tests supports the brand, with the indicator standing at 0.06. This daily price chart clearly demonstrates the dynamics of this diagnostics market player.

Efficient express logistics for biomaterials ensure Burning Rock Biotech achieves high diagnostic accuracy, which converts into growth in tangible assets. The current value of 0.06 reflects the difference between all assets and liabilities, demonstrating the real value of equity, which allows for an assessment of the business's internal stability through the book capitalization trend.